logo

Merck & Co Inc. (MRK)



Trade MRK now with
  Date
  Headline
1/19/2018 6:48:04 AM Merck Says First-Time Data For KEYTRUDA In Patients With Advanced HCC To Be Presented At 2018 ASCO GI Symposium
1/16/2018 6:47:03 AM Merck Says Pivotal Phase 3 KEYNOTE-189 Trial Investigating KEYTRUDA Met Its Dual Primary Endpoints
1/9/2018 6:47:05 AM Eisai And Merck Receive Breakthrough Therapy Designation From FDA For LENVIMA And KEYTRUDA As Combination Therapy
1/8/2018 6:48:24 AM Merck Says KEYTRUDA Significantly Improved Recurrence-Free Survival Compared To Placebo
1/8/2018 6:32:06 AM Merck: FDA Accepts For Review Two NDAs For Doravirine
1/7/2018 9:50:22 AM New Drugs Approved In December
1/2/2018 7:01:21 AM Merck’s KEYTRUDA Approved In Japan For Use In Treatment Of Patients With Urothelial Carcinoma
12/22/2017 7:01:13 AM Merck : FDA Oks SGLT2 Inhibitor STEGLATRO And Fixed-Dose Combination STEGLUJAN For Adults With Type 2 Diabetes
12/11/2017 6:33:33 AM Merck Reports Findings From Phase 2 KEYNOTE-170 Trial Investigating Use Of KEYTRUDA (pembrolizumab)